Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Read at CNBC(opens in a new tab)
Full coverage
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction (opens CNBC in a new tab)
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
